BIMEKIZUMAB

bimekizumab 320 mg/2 mL injection, 2 mL pen devices

BIMEKIZUMAB (15262G)

bimekizumab 320 mg/2 mL injection, 2 mL pen devices
15262G
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Whole body

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Face, hand, foot

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Whole body or Continuing treatment, Face, hand, foot - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 2 DPMQ: $3,395.86 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Bimzelx